PixarBio Corporation Announces 7-Day NeuroRelease™ Pain, and USPTO Patent Filing for “Sprinkle On” 3-Day NeuroRelease™ Pain Sterile Powder

CAMBRIDGE, Mass.–(BUSINESS WIRE)–PixarBio Corporation announced the expansion of our NeuroRelease™ Pain
Platform to include a 7-Day post-surgical pain treatment and a 3-Day
sterile powder known as “Sprinkle-On” NeuroRelease™. With recent patent
application filings to the USPTO for “Sprinkle On” NeuroRelease™, a
sterile powder form to be sprinkled into incisions and wounds, both
7-Day and “Sprinkle-On” products are now covered in the PixarBio USPTO
patent applications portfolio.
NeuroRelease™ Platform, non-addictive, non-opiate pain platform
NeuroRelease™ is a morphine strength, non-addictive pain treatment for
the hospital setting, for the battlefield, or for acute and chronic
pain. First product FDA approval for the platform will be for a 14-day
post-surgical pain treatment is expected in 2018. A major benefit of
NeuroRelease™ is there is no effect on locomotion nerve fibers, so
patients can still control their locomotion nerve fibers movements and
move around with a morphine strength treatment that is non-addictive.
NeuroRelease™ only effects sensory or pain signaling nerve fibers.
“Sprinkle-On” Version of NeuroRelease™
Like Vancomycin, an antibiotic that is sprinkled into incisions and
wounds to reduce infection, NeuroRelease™ can be sprinkled into
incisions and wounds to provide pain treatment. We envision “Sprinkle
On” NeuroRelease™, a 3-day sterile powder that can be used in a range of
non-hospital settings such as the battlefield where the current use of
morphine leads to immobilized soldiers. Since, NeuroRelease™ does not
affect locomotion fibers, soldiers can move themselves to safety.
Emergency room trauma is a logical application in the clinic and
“Sprinkle On” NeuroRelease™ will be a welcomed new pain treatment option
for physicians performing surgery.
Market analysis confirms significant market demand for an incisional or
wound pain products. A 3-day “Sprinkle On” pain treatment, is expected
to receive FDA approval in 2019. In addition to the “Sprinkle On”
application, the versatile 3-day pain treatment is also engineered for
use in nerve blocks and soft tissue infiltrations.
PixarBio NeuroRelease™ pain platform also includes 4-8 hour, 3-day,
7-day, 14-day and 90-Day pain treatments all have expected FDA approvals
in 2020. NeuroRelease™ is biodegradable, and it’s non-toxic so
NeuroRelease™ is the only non-opiate under review at the FDA that can be
re-injected to extend treatment timelines. “NeuroRelease™ represents the
holy-grail of pain treatment, and the quality of the KOL’s we signed
this summer to our clinical advisory board, speaks volumes to the
potential market opportunity and to the clinical impact of
NeuroRelease™,” said CEO Frank Reynolds.
Last month PixarBio Corporation was awarded the Boston Business
Journal’s “2016 Best Places to Work”. The award recognizes PixarBio as
one of the region’s best firms, offering the greatest professional
opportunities and work environments to innovate; the company is excited
to bring “Sprinkle On” NeuroRelease™ to market in 2019.
About PixarBio Corporation
Cofounded by Frank M. Reynolds,
MIT’s Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione,
Haining Dai, Xi Chen, and Dr. Amer Khalil. PixarBio researches and
develops targeted delivery systems for drugs, cells, or biologics to
treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For
more information visit www.pixarbio.com.